Latent Labs founder Simon Kohl, a key figure in the AlphaFold project, presented at CVPR 2026 on using generative AI for molecular design. He highlighted the inefficiencies in traditional drug discovery, which takes over a decade and billions of dollars with a high failure rate. Kohl introduced Latent Labs' models, Latent-X1 and Latent-X2, which show promise in designing drug molecules with high accuracy, and unveiled Latent-Y, an AI agent capable of autonomous antibody design from natural language prompts. AI
IMPACT Generative AI is poised to revolutionize drug discovery by enabling faster, cheaper, and more precise design of therapeutic molecules.
RANK_REASON The cluster describes a presentation at a conference about new AI models and approaches for molecular design, including a new AI agent. [lever_c_demoted from research: ic=1 ai=1.0]
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
